Insiders Immutep Limited

Equities

Delayed Australian S.E. Other stock markets 01:25:58 2024-05-22 am EDT			5-day change	1st Jan Change
0.475 ^AUD	+1.06%		+6.74%	+37.68%

May. 17	Capital One Initiates Immutep at Overweight Rating With $10 Price Target	MT
May. 15	Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data	MT

Encouraging results for Immutep's cancer therapies	Mar. 25	FI
Immutep Limited Appoints Florian Vogl as Chief Medical Officer	23-04-26	CI
Immutep Limited Announces Changes to the Board	23-04-10	CI
Immutep Appoints Frederic Triebel as Executive Director	22-09-12	CI
Immutep Limited Announces Executive Changes	22-05-17	CI
Immutep Limited Appoints Lucy Turnbull as Non-Executive Director	22-02-24	CI
Immutep Limited Announces Demise of Grant Chamberlain, Non-Executive Director	22-02-01	CI
Immutep Limited Announces Executive Changes	21-01-04	CI
Prima BioMed Ltd will Change its Name to Immutep Ltd	17-12-01	CI
Prima Biomed Limited Announces Cessation of Lucy Turnbull as Director	17-11-22	CI
Immutep Limited Announces Cessation of Mr. Albert Wong as Director	17-11-22	CI
Prima BioMed Ltd. Appoints Grant Chamberlain as Non-Executive Director	17-08-20	CI
Prima Biomed Ltd. Announces Formation of Clinical Advisory Board	17-05-31	CI
Prima Biomed Ltd. Appoints Jay Campbell as General Manager, US Operations	17-03-06	CI
Prima Biomed Ltd. Announces Executive Changes	16-03-08	CI
Stuart Roberts Appoints Stuart Roberts as Global Head of Investor Relations	15-01-19	CI
Frédéric Triebel Joins Prima Biomed Ltd as its New Chief Scientific Officer and Chief Medical Officer	14-12-17	CI
Prima Biomed Ltd. Announces Executive Changes	14-07-09	CI
Prima BioMed Ltd Appoints Professors Eric Pujade-Lauraine, Christian Marth and Ignace Vergote to its Clinical Advisory Board	14-03-25	CI
Bradley J. Monk to Join Prima Biomed's Clinical Advisory Board	14-02-19	CI

No results for this search